U.S. market Closed. Opens in 1 day 5 minutes

IMTXW | immatics biotechnologies GmbH Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for IMTXW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak.

Valuation (16%)

Company Industry
P/E Ratio (TTM) -11.35 -15.27
PEG Ratio (TTM) -0.29 -4.35
P/S Ratio (TTM) 6.77 45.97
P/B Ratio (TTM) 1.66 28.96
P/FCF Ratio (TTM) -17.51 -2.59
Price to 5YR AVG Earnings Ratio -0.13 -5.56
Price to 5YR AVG FCF Ratio -103.72 -12.33

Profitability (25%)

Company Industry
ROA (TTM) -9.67% -19.06%
ROE (TTM) -15.98% 15.70%
Net Profit Margin (TTM) -48.25% -813.88%
ROIC 5YR AVG 110.08% 3.12%

Growth (47%)

4QTR AVG 3YR AVG 5YR AVG
EPS -113.38% -262.53% -193.87%
Revenue 97.77% 156.67% 159.68%
Net Income -86.17% -188.32% -156.81%
Cash Flow 53.69% 8.98% 33.52%

Health (26%)

Company Industry
Current Ratio (TTM) 3.98 5.56
Quick Ratio (TTM) 3.98 5.34
D/E Ratio (TTM) N/A 0.95
Interest Coverage (TTM) -77.74 -6.44
Piotroski F-Score 2 5
Altman Z-Score 1.17 12.45
LTL to 5YR AVG FCF -2.09 0.11
Shares Outstanding Growth 5YR AVG 6.81% 37.46%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙